Tirzepatide 10mg

Buy high-purity Tirzepatide 10mg in Australia. Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About Tirzepatide

Tirzepatide (research code LY-3298176) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIP-R) and the glucagon-like peptide-1 receptor (GLP-1R). Optic Labs supplies tirzepatide as a high-purity lyophilised powder in 10mg vials, packaged for in vitro and preclinical laboratory research.

Each batch is independently HPLC-tested for purity and identity, with certificates of analysis available on request.

Tirzepatide is one of the most extensively studied compounds in the recent metabolic research literature, with published Phase 3 clinical trial data examining glycaemic control and body composition in human study populations. Optic Labs supplies tirzepatide for laboratory research only — not for human consumption, clinical use, or any therapeutic application.

Product specifications

• Compound: Tirzepatide (LY-3298176)
• CAS number: 2023788-19-2
• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: ~4813.5 g/mol
• Mechanism (research context): Dual agonist — GIP-R + GLP-1R
• Form: Lyophilised (freeze-dried) white powder
• Purity: >99% by HPLC
• Available sizes: 10mg vial
• Storage: Store unreconstituted vials at 2–8°C; protect from light. Reconstituted solution stored at 2–8°C and used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

Tirzepatide was developed as a dual incretin agonist, combining GIP and GLP-1 receptor activity in a single molecule. Published preclinical and clinical research has examined tirzepatide in the context of:

• GIP and GLP-1 receptor binding, signalling and downstream pathways
• Glycaemic control and insulin sensitivity in type 2 diabetes research models
• Body composition and adiposity in animal models and clinical study populations
• Hepatic lipid metabolism and NAFLD/MASH research models
• Gastric emptying and appetite-regulation research
• Phase 1, 2 and 3 clinical pharmacokinetic, glycaemic and weight-change studies (SURPASS and SURMOUNT programmes)

Reconstitution and handling

Tirzepatide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in any laboratory protocol. A 10mg vial reconstituted in 2mL of bacteriostatic water yields a working concentration of 5mg/mL; 1mL yields 10mg/mL.

Exact volumes should be calculated for each protocol — our reconstitution calculator guide walks through the maths. Reconstituted vials should be stored refrigerated at 2–8°C and protected from light.

Comparisons and related research compounds

Tirzepatide sits within the broader class of incretin and metabolic peptides. Researchers may also be interested in:

• Retatrutide — triple agonist (GLP-1 + GIP + glucagon), successor research compound
• AOD-9604 — fragment growth-hormone analogue, fat-loss research
• Tesamorelin — GHRH analogue, lipolysis research
• CJC-1295 + Ipamorelin — growth-hormone-releasing research peptide combination
• 5-Amino-1MQ — NNMT inhibitor, metabolic research

Frequently asked questions

Is tirzepatide legal in Australia?

Tirzepatide has been registered with the Therapeutic Goods Administration (TGA) as a prescription-only therapeutic product in Australia under separate brand registrations. Optic Labs does not supply tirzepatide as a therapeutic, prescription or compounded product. Optic Labs supplies tirzepatide strictly as a research chemical for in vitro and preclinical laboratory research — not for human consumption, clinical use or any therapeutic application. For a detailed overview, see our guide to peptide legality and TGA compliance in Australia.

What is tirzepatide?

Tirzepatide (LY-3298176) is a synthetic 39-amino-acid peptide developed as a dual agonist of the GIP and GLP-1 receptors. In published research it has been investigated for its effects on glycaemic control, body composition, hepatic lipid metabolism and gastric emptying.

How does tirzepatide differ from semaglutide and retatrutide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP agonist. Retatrutide adds a third receptor target — the glucagon receptor — making it a triple agonist. The published research literature has examined each compound across its own clinical programme, and the receptor profiles differ in mechanism rather than being directly interchangeable.

How is tirzepatide supplied?

Optic Labs supplies tirzepatide as a lyophilised powder in a glass research vial at the 10mg size. Each vial is sealed and shipped with a tamper-evident seal. Certificates of analysis showing HPLC purity testing are available on request.

How much bacteriostatic water do I mix with a tirzepatide 10mg vial?

Reconstitution volume depends on the working concentration required by the research protocol. As a starting reference: 10mg in 2mL of bacteriostatic water yields 5mg/mL; 10mg in 1mL yields 10mg/mL. Our reconstitution guide covers the calculations.

How should reconstituted tirzepatide be stored?

Unreconstituted vials should be stored at 2–8°C and protected from light. Once reconstituted, the solution should be refrigerated at 2–8°C and used within approximately 30 days. For full storage protocols, see our peptide storage guide.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease.

Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.